跳至主要内容
临床试验/JPRN-UMIN000015316
JPRN-UMIN000015316招募中未知

Effect of EPA/DHA treatment on coronary hyperintense plaque detected by non-contrast T1-weighted magnetic resonance imaging - Effect of EPA/DHA treatment on coronary hyperintense plaque detected by magnetic resonance imaging

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center0 个研究点目标入组 150 人开始时间: 2014年10月10日最近更新:

试验速览

阶段
未知
状态
招募中
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional,observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1.Use of EPA preparation within 12 weeks before informed consent 2.Scheduled to undergo percutaneous coronary intervention (PCI) or coronary-artery bypass grafting (CABG) during the observation period 3.Presence of type 1 diabetes mellitus or type 2 diabetes mellitus with uncontrolled hyperglycemia (HbA1C more than;8.0%) 4.Presence of bleeding (e.g., hemophilia, capillary fragility, gastrointestinal tract ulcer, urinary tract bleeding, hemoptysis, vitreous hemorrhage) 5.History of hypersensitivity to any component of the investigational product 6.Other patients who are inappropriate for participation in this study in the opinion of the principal investigator or investigator.

研究者

发起方
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center

相似试验